STX1A (1-265) is typically expressed in E. coli due to its prokaryotic expression efficiency and cost-effectiveness. Key features include:
Host System | Purity | Post-Translational Modifications | Applications |
---|---|---|---|
E. coli | >95% | None | Structural studies, antibody production |
Tobacco plants | >80% | Glycosylation (partial) | Native-like conformation studies |
HEK-293 cells | >80% | Full glycosylation, phosphorylation | Functional assays (e.g., exocytosis) |
Data from commercial sources highlight E. coli as the primary choice for high-yield production .
STX1A (1-265) Human is pivotal in:
SNARE Complex Assembly: Forms a 4-helix bundle with SNAP-25 and VAMP2, driving synaptic vesicle fusion .
Calcium-Dependent Exocytosis: Binds synaptotagmin to regulate neurotransmitter release timing .
Pain Sensitivity: Overexpression in TRPV1+ nociceptive neurons causes pain insensitivity in 7q11.23 duplication syndrome (Dup7) .
Pain Insensitivity: Dup7 patients with STX1A triplication exhibit reduced nociceptive signaling due to impaired TRPV1-mediated exocytosis .
Neurodegenerative Diseases: Altered STX1A levels in Alzheimer’s disease (AD) brains suggest synaptic dysfunction .
Intelligence Correlation: In Williams syndrome, STX1A expression levels predict 15.6% of cognitive variance .
STX1A (1-265) is used in:
STX1A contains several key domains that are critical to its function:
SNARE domain: Essential for forming the SNARE complex with SNAP-25 and VAMP, driving membrane fusion
Juxtamembrane domain (JMD): Connects the SNARE domain to the transmembrane region
Transmembrane domain (TMD): Anchors the protein in the plasma membrane
N-terminal Habc domain: Regulates protein conformation and interactions with regulatory proteins like Munc18-1
Research has shown that the spatial relationship between these domains is critical for proper function. For example, mutations that disrupt the coupling between the SNARE domain and TMD or between JMD and TMD lead to significant alterations in neurotransmission .
Multiple expression systems have been validated for producing STX1A (1-265), each with distinct advantages:
Expression Host | Purity Achieved | Applications | Advantages |
---|---|---|---|
E. coli | >95% | SDS-PAGE, WB, ELISA | High yield, cost-effective |
Yeast | >90% | ELISA | Produces protein very close to the natural form |
HEK-293 Cells | >90% | SDS, WB | Mammalian post-translational modifications |
Wheat germ | Not specified | WB, ELISA, AP, AA | Alternative for difficult proteins |
For functional studies of neurotransmission, proteins expressed in E. coli and purified to >95% purity have been successfully utilized in multiple studies .
To effectively study STX1A function in vesicle fusion:
Use lentiviral expression systems in STX1-null neurons to eliminate background effects from endogenous protein
Compare wild-type STX1A with mutant variants (particularly mutations in the JMD or coupling between domains)
Measure electrophysiological parameters including:
Excitatory postsynaptic current (EPSC) amplitude
EPSC charge analysis
Vesicular release probability (Pvr)
Frequency of miniature EPSCs (mEPSCs)
Maintain physiological calcium concentrations (1-2 mM) during experiments
These methodologies have revealed that even minor alterations in STX1A structure, such as the insertion of three amino acids (GSG) at specific positions, can dramatically alter neurotransmission properties .
STX1A is a critical component of the SNARE complex, which provides the mechanical force necessary for synaptic vesicle fusion with the plasma membrane. Recent research has revealed several key mechanisms:
The force transfer from SNARE complex formation to membrane fusion is strictly regulated by the length and positioning of the JMD of STX1A
Even small alterations in this region (e.g., insertion of one extra helical turn) can abolish EPSC amplitude
Different regions of STX1A have distinct roles in regulating different aspects of neurotransmission
Specifically, experiments with STX1A GSG259 (insertion in the SNARE domain-TMD coupling region) and STX1A GSG265 (insertion in the JMD-TMD coupling region) demonstrated that these mutations reduced EPSC amplitude to almost zero, while having differential effects on EPSC charge (reduced by ~61% and ~40% respectively) .
STX1A regulates spontaneous release through two distinct mechanisms:
Regulation through the C-terminal half of its SNARE domain
Regulation through the juxtamembrane domain (JMD) and transmembrane domain (TMD)
Experimental evidence shows that uncoupling of the SNARE domain and TMD (STX1A GSG259) had no significant effect on spontaneous neurotransmission, while uncoupling of the JMD and TMD (STX1A GSG265) increased miniature EPSC frequency approximately threefold compared to wild-type STX1A .
This differential regulation suggests that STX1A may serve as a molecular switch between different modes of neurotransmitter release, with distinct structural regions mediating different aspects of vesicle fusion.
Several lines of evidence suggest a role for STX1A in autism spectrum disorders, particularly high-functioning autism (HFA):
Genetic evidence: Transmission disequilibrium tests identified associations between specific STX1A SNPs and HFA:
SNP ID | p-value | Association with HFA |
---|---|---|
rs2293485 | 0.034 | Nominal association |
rs4717806 | 0.033 | Nominal association |
Expression analysis: STX1A mRNA expression in lymphocytes of drug-naive HFA patients was significantly higher (p=0.001) than in age- and sex-matched controls
Developmental correlation: SNPs showing associations were specifically related to early developmental abnormalities (ADI-R_D scores), suggesting STX1A might influence early neurodevelopmental processes .
The link between STX1A and serotonergic function provides insight into its potential role in autism:
STX1A is known to regulate the serotonin transporter (5-HTT), a major therapeutic target in autism
Humans normally undergo a period of high brain serotonin synthesis capacity during early childhood, which is disrupted in autistic children
STX1A might influence this serotonergic system during critical developmental periods
Research suggests that abnormal STX1A expression may contribute to autism pathophysiology by disrupting serotonergic neurotransmission during critical developmental windows. This is supported by the observation that SNPs associated with HFA correlate with early developmental abnormalities rather than specific symptoms, suggesting a role in general pathophysiology rather than specific symptom manifestation .
The interaction between STX1A and Munc18-1 is crucial for proper synaptic vesicle fusion. To effectively study this interaction:
Use purified recombinant proteins with various tags (His, GST) expressed in prokaryotic or eukaryotic systems
Employ protein-protein interaction assays:
Pull-down assays with immobilized tagged proteins
Surface plasmon resonance for real-time interaction kinetics
Isothermal titration calorimetry for thermodynamic parameters
For functional studies in neuronal contexts:
Generate domain deletion mutants (e.g., ΔHabc) to assess functional consequences
Utilize lentiviral expression in STX1-null neurons for electrophysiological assessment
Implement FRET-based approaches to visualize interactions in living cells
These techniques have revealed that STX1A and Munc18-1 are interdependent components of the synaptic vesicular release machinery, and their interaction is essential for proper neurotransmission .
Strategic design of STX1A mutants has proven valuable for understanding domain-specific functions:
This systematic approach has revealed that even subtle modifications (e.g., insertion of one extra helical turn into the JMD) can lead to position-specific physiological phenotypes, demonstrating the precise spatial requirements for STX1A function in neurotransmission .
The human recombinant Syntaxin-1A (1-265 a.a) is a full-length protein comprising 265 amino acids. It is expressed in Escherichia coli and has a purity greater than 95%, making it suitable for various biochemical applications such as SDS-PAGE . The protein is also known by several alternative names, including Neuron-specific antigen HPC-1, STX1A, and STX1 .
Syntaxin-1A is primarily found in the brain and is essential for synaptic vesicle exocytosis. It interacts with other SNARE proteins, such as SNAP-25 and VAMP (vesicle-associated membrane protein), to form a SNARE complex. This complex brings the vesicle and plasma membranes close together, facilitating their fusion and the subsequent release of neurotransmitters .
The protein’s structure includes a transmembrane domain that anchors it to the plasma membrane and a cytoplasmic domain that interacts with other SNARE proteins. The interaction between Syntaxin-1A and its partners is highly regulated and crucial for the precise timing of neurotransmitter release, which is essential for proper neuronal communication .
Recombinant Syntaxin-1A (1-265 a.a) is widely used in research to study the mechanisms of synaptic transmission and the role of SNARE proteins in vesicle fusion. It is also used in various assays to investigate the interactions between SNARE proteins and other regulatory factors involved in neurotransmitter release .
Understanding the function and regulation of Syntaxin-1A is important for elucidating the molecular basis of synaptic transmission and for developing potential therapeutic strategies for neurological disorders that involve synaptic dysfunction.